Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, phone calls, and what-not has, of course, returned. Despite the coronavirus, the world keeps spinning, in some fashion. So time to grab a cup of stimulation — hazelnut creme is the reliable choice today — and get things done. On that note, here are a few tidbits to help you along. Hope your day is manageable and productive.

Public health experts are warning Congress not to treat emergency coronavirus aid like business as usual, STAT says. Partisan bickering has often frustrated attempts to speedily approve emergency spending packages. Congress dawdled for seven months due to an acrimonious fight over funding for Zika in 2016, leaving health departments cash-strapped and forced to cut existing health programs. The delay left the federal government no choice but to plunder funds meant for cancer research, heart disease, and fighting HIV to pay for their response efforts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.